Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes

This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes

Inclusion Criteria:

• Age from 65 years to the upper age limit recommended by local prescribing information for metformin
• Drug naive patients with type 2 diabetes.
• Body mass index (BMI) in the range of 22-40 kg/m2.
• HbA1c in the range of 7 to 9% inclusive
• FPG <270 mg/dL (15 mmol/L)

Exclusion Criteria:

• A history of type 1 diabetes
• Evidence of significant diabetic complications
• Treatment with insulin or any other oral antidiabetic agents

Other protocol-defined inclusion/exclusion criteria may apply